백스터
Merck KGaA currently relies on third-party manufacturers to supply the product candidate: On [[Baxter International|Baxter International Inc. (Baxter)]], for the manufacture of tecemotide, and on [[GlaxoSmithKline|GlaxoSmithKline plc (GSK)]] for the manufacture of the adjuvant in tecemotide called monophosphoryl lipid A (MPL). If tecemotide is not approved until 2015, GSK may terminate its obligation to supply the adjuvant MPL. In this case, Oncothyreon would retain the necessary licenses from GSK required to have the adjuvant MPL manufactured, but the transfer of the process to a third party would delay the development and commercialization of tecemotide.